Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda save search
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
Published: 2023-01-27 (Crawled : 20:00) - biospace.com/
LLY | News | $342.1 -1.7% 0.12% 2.3M
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
fda for
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
Published: 2023-01-26 (Crawled : 23:00) - biospace.com/
SANA | $4.8 4.12% 3.96% 1.2M
|
|
| O: 1.06%
H: 1.05%
C: -3.15%
sc291 fda clearance drug for application therapy
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
Published: 2023-01-26 (Crawled : 15:20) - biospace.com/
ABT | News | $109.95 -1.01% 0.0% 4.9M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
fda for living diabetic
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
CNTA | $3.82 -4.5% -4.71% 1.2M
|
Manufacturing
|
| O: 2.08%
H: 3.05%
C: 1.78%
lb101 lockbody fda clearance pharmaceuticals for application trial tumors
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Published: 2023-01-26 (Crawled : 13:00) - biospace.com/
SYRS | $4.5 1.81% 1.78% 90K
|
Health Technology
|
| O: 5.79%
H: 2.41%
C: -3.28%
treatment fda designation for
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
OCUP | $3.44 14.29% 12.5% 340K
|
Health Technology
|
| O: -18.7%
H: 10.0%
C: 0.33%
apx3330 fda for topline meeting trial results diabetic
Modular Medical Provides Update on FDA Submission Strategy
Published: 2023-01-25 (Crawled : 14:20) - biospace.com/
ARVL | News | $0.4041 3.62% 3.49% 14M
|
Manufacturing
|
| O: -3.2%
H: 0.0%
C: 0.0%
fda medical update submission
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Published: 2023-01-25 (Crawled : 13:20) - prnewswire.com
IKT | News 0 d | $0.69 -2.82% -2.9% 420K
|
Health Technology
|
| O: 5.35%
H: 0.0%
C: 0.0%
fda disease ikt-148009 lifted parkinson's therapeutics
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
IMRN | $2.12 -4.72% 8.3K
|
Health Technology
| Email alert
Add to watchlist
fda research for medical
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
TNGX | $6.52 -4.68% -4.91% 110K
|
|
| O: -2.29%
H: 0.0%
C: 0.0%
tng462 fda clearance drug for application therapeutics
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
CDTX | $1.2 -0.83% -0.83% 1.6M
|
Health Technology
|
| O: 17.44%
H: 0.0%
C: 0.0%
treatment fda candidiasis for approval therapeutics rezafungin candidemia
Casana Sustains Accelerated Momentum Ahead of Desired Product FDA Clearance
Published: 2023-01-24 (Crawled : 18:00) - biospace.com/
CEAI | $ 0%
|
| Email alert
Add to watchlist
fda clearance momentum
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2023-01-24 (Crawled : 16:00) - biospace.com/
CGEM | $11.47 2.87% 2.79% 110K
|
|
| O: 1.43%
H: 5.09%
C: 4.05%
cln-978 treatment fda clearance drug for t-cell application
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
KURA | $13.63 -2.71% -2.79% 1.1M
|
Health Technology
|
| O: 1.79%
H: 0.98%
C: -0.91%
ko-2806 fda clearance for application
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
Published: 2023-01-23 (Crawled : 14:00) - biospace.com/
TCRX | $1.78 2.89% 2.81% 140K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
treatment fda clearance drug for therapeutics tumors
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
Published: 2023-01-23 (Crawled : 14:00) - biospace.com/
CVKD A 3 d | $2.62 -7.75% -8.4% 120K
|
|
| O: -13.85%
H: 12.75%
C: -27.54%
fda designation disease for cardiac renal granted therapeutics origin
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Published: 2023-01-23 (Crawled : 13:20) - prnewswire.com
BPMC | $47.79 0.08% 0.08% 280K
|
Health Technology
|
| O: 0.24%
H: 1.29%
C: -0.15%
ayvakit treatment fda drug for application
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published: 2023-01-20 (Crawled : 07:00) - prnewswire.com
ALPMF | $15.03 0
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $15.16 0
|
Manufacturing
| Email alert
Add to watchlist
at845 treatment fda disease for lifted trial
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
OPNT | $20.245 -0.17% -0.17% 66K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
opnt003 fda pharmaceuticals opioid for review
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
SGEN M | $140.75 0.76% 0.75% 870K
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
tukysa fda for approval cancer
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.